NEW YORK (GenomeWeb News) – Molecular diagnostics firm Biocartis today announced that it has licensed from Hospital del Mar in Spain the rights to an EGFR biomarker for colon cancer.

The Lausanne, Switzerland-based firm plans to develop an EGFR mutation test that can help doctors further refine the best responder population among colon cancer patients receiving EGFR inhibitors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times reports that as China invests in science, it also is dealing with research fraud.

In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.

The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.

Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.